Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues

By
A A A

Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics ( PTIE ) rose 82.3% in its July 2000 debut. The company raised $106 million in an upsized IPO that valued the company at a market cap of $542 million, after originally setting terms for a deal that would have generated $75 million in proceeds at a market cap of $441 million. Agios' opening day vaults it ahead of last week's OncoMed ( OMED ), which saw its shares rise 59.9% on its first day of trading, for the best biotech first-day return in 2013. Agios is the fifth 2013 biotech deal to gain nearly 50% or more in its market debut.

Top Five Biotech First-Day Returns of 2013
Company Ticker Description First-Day Return Total Return
Agios Pharmaceuticals AGIO Pre-clinical cancer biotech 74% 74%
OncoMed Pharmaceuticals OMED Cancer biotech 60% 38%
bluebird bio BLUE Gene therapy biotech 58% 87%
Epizyme EPZM Early-stage cancer biotech
53% 134%
Prosensa RNA Late-stage orphan drug biotech
48% 110%




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: AGIO , OMED , PTIE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

3 Great Stay-at-Home Jobs
3 Great Stay-at-Home Jobs           

Stocks

Referenced

Most Active by Volume

121,542,429
  • $114.64 ▼ 3.21%
75,240,655
  • $40.31 ▲ 2.02%
71,068,407
  • $3.49 ▲ 4.49%
68,252,066
  • $17.80 ▲ 0.17%
36,462,005
  • $37.10 ▲ 11.92%
33,292,485
  • $21.75 ▲ 9.57%
32,729,543
  • $5.25 ▲ 1.94%
32,548,015
  • $47.54 ▲ 1.56%
As of 8/4/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com